SCHEMBL25393293

SCHEMBL25393293

Cc1cc(F)c(N)cc1-c1ccccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.44
NPC1 O15118 5/20 0.44
TDO2 P48775 1/20 0.41
LMNA P02545 3/20 0.41
METAP1 P53582 2/20 0.41
CCR1 P32246 2/20 0.41
CCR5 P51681 2/20 0.41
CCR8 P51685 2/20 0.41
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41
BLM P54132 1/20 0.41
HIF1A Q16665 1/20 0.41
DOHH Q9BU89 1/20 0.41
P4HTM Q9NXG6 1/20 0.41
L3MBTL1 Q9Y468 5/20 0.40
RAB9A P51151 3/20 0.40
HTT P42858 3/20 0.40
ALDH1A1 P00352 2/20 0.40
MAP3K5 Q99683 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17636297 0.86 KDM4E (0.49) KDM4ENPC1LMNAMETAP1CCR1
SCHEMBL25395443 0.85 KDM4E (0.47) KDM4ENPC1TDO2LMNAMETAP1
SCHEMBL12320133 0.85 KDM4E (0.47) KDM4ENPC1LMNAMETAP1CCR1
SCHEMBL17427076 0.80 KDM4E (0.57) KDM4ENPC1TDO2LMNAMETAP1
SCHEMBL31387661 0.79 BRD4 (0.35)
SCHEMBL25395333 0.79 BRD4 (0.35)
SCHEMBL13581443 0.79 KDM4E (0.55) KDM4ENPC1TDO2LMNAMETAP1
SCHEMBL30776779 0.79 KDM4E (0.55) KDM4ENPC1TDO2LMNAMETAP1
SCHEMBL7085984 0.78 KDM4E (0.47) KDM4ENPC1TDO2LMNAMETAP1
SCHEMBL30296459 0.77 NPC1 (0.43) KDM4ENPC1TDO2LMNAMETAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171462-A1 COMPOUNDS, COMPOSITIONS, AND METHODS TENVIE THERAPEUTICS, INC. 2025-05-29 US disclosed
EP-4486722-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Nico Therapeutics, Inc. (US) 2025-01-08 EP disclosed
CN-119137101-A Compounds, compositions, and methods 尼科治疗有限公司 2024-12-13 CN disclosed
WO-2023168298-A2 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2023-09-07 WO disclosed
WO-2023168298-A2 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2023-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171462-A1 COMPOUNDS, COMPOSITIONS, AND METHODS SARM1, SARS1, TIAM1 KDM4E 3128/4885NPC1 1259/4885TDO2 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.